NCT05844332 2025-12-22
LUTATHERA Injection General Use Result Survey
Novartis
Completed
Clinical Trials
9 trialsNCT02230176 2025-04-20
OCCLURANDOM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT04946305 2024-08-09
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
Novartis
Completed
NCT04385992 2023-06-27
NeoLuPaNET
IRCCS San Raffaele
Phase 2 Completed
NCT05816720 2023-04-18
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Completed
NCT01237457 2023-03-20
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Completed
NCT01842165 2022-11-10
LUMEN
Jules Bordet Institute
Phase 3 Completed
NCT03590119 2022-11-08
LUTIA
UMC Utrecht
Phase 2/3 Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed